Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P00492

UPID:
HPRT_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P00492; A6NHF0; B2R8M9

BACKGROUND:
The enzyme Hypoxanthine-guanine phosphoribosyltransferase is central to nucleotide recycling, facilitating the conversion of hypoxanthine and guanine to their respective monophosphate forms. This process is vital for maintaining nucleotide pools within the cell.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Hypoxanthine-guanine phosphoribosyltransferase could open doors to potential therapeutic strategies for treating Lesch-Nyhan syndrome and HPRT-related hyperuricemia, diseases characterized by uric acid accumulation and neurological complications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.